Monday, October 10, 2016

Bristol plunges, Merck jumps, on contrasting lung cancer data

… 10 percent after researchers said lung cancer patients fared worse on its … previously treated for their advanced lung cancer. Both drugs were already approved … ' the segment of first-line lung cancer patients who have high PD-L1 … several types of cancer, but lung cancer is considered by far the …

No comments:

Post a Comment